Sanofi
- Country
- 🇫🇷France
- Ownership
- Public
- Employees
- 87.9K
- Market Cap
- $141.3B
- Website
- http://www.sanofi.com
- Introduction
Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.
TREAD-20 Extension - Treatment of Knee Pain Due to Osteoarthritis
- Conditions
- Osteoarthritis
- First Posted Date
- 2009-01-28
- Last Posted Date
- 2009-03-19
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 40
- Registration Number
- NCT00830830
- Locations
- 🇺🇸
Sanofi-Aventis Inc, Bridgewater, New Jersey, United States
Weekly Docetaxel and Four Weekly Carboplatin in Non-small Cell Lung Cancer Carbo-Tax
- Conditions
- Lung Neoplasms
- First Posted Date
- 2009-01-22
- Last Posted Date
- 2010-07-27
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 49
- Registration Number
- NCT00826852
- Locations
- 🇹🇷
Sanofi-Aventis Administrative Office, Istanbul, Turkey
Efficacy and Safety of SR58611 Compared to Placebo and Paroxetine
- Conditions
- Major Depressive Disorders
- Interventions
- First Posted Date
- 2009-01-19
- Last Posted Date
- 2009-03-25
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 317
- Registration Number
- NCT00825058
- Locations
- 🇷🇸
Sanofi-Aventis Administrative Office, Belgrade, Serbia
Efficacy and Safety of One Single Dose of SR58611 Compared to Placebo and Paroxetine
- Conditions
- Major Depressive Disorders
- Interventions
- First Posted Date
- 2009-01-19
- Last Posted Date
- 2009-03-25
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 306
- Registration Number
- NCT00825019
- Locations
- 🇺🇸
Sanofi-Aventis Administrative Office, Bridgewater, New Jersey, United States
Safety Evaluation of Clopidogrel Sulfate in Patients With Stable Angina/Old Myocardial Infarction to Whom Percutaneous Coronary Intervention is Being Planned
- Conditions
- Stable AnginaMyocardial Infarction
- Interventions
- First Posted Date
- 2009-01-14
- Last Posted Date
- 2011-07-26
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 1003
- Registration Number
- NCT00821834
- Locations
- 🇯🇵
Sanofi-Aventis Administrative Office, Tokyo, Japan
An Eight-week Study of SSR411298 as Treatment for Major Depressive Disorder in Elderly Patients
- Conditions
- Major Depressive Disorder
- Interventions
- First Posted Date
- 2009-01-14
- Last Posted Date
- 2013-03-15
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 527
- Registration Number
- NCT00822744
- Locations
- 🇺🇦
Sanofi-Aventis Administrative Office, Kiev, Ukraine
Trial of Weekly Taxotere and Irinotecan (CPT-11) in Patients With Advanced Non-small Cell Lung Cancer
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- First Posted Date
- 2009-01-09
- Last Posted Date
- 2011-01-11
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 35
- Registration Number
- NCT00819728
- Locations
- 🇺🇸
Sanofi-Aventis US, Bridgewater, New Jersey, United States
Safety Study of Recombinant M2e Influenza-A Vaccine in Healthy Adults
- Conditions
- Influenza
- Interventions
- Biological: Saline placebo
- First Posted Date
- 2009-01-08
- Last Posted Date
- 2012-01-19
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 87
- Registration Number
- NCT00819013
- Locations
- 🇺🇸
Johnson County Clin-Trials, Lenexa, Kansas, United States
🇺🇸Miami Research Associates, Miami, Florida, United States
🇺🇸Northwest Kinetics, Tacoma, Washington, United States
Docetaxel + Oxaliplatin + S-1 in Potentially Operable Gastric or Gastroesophageal Adenocarcinoma
- First Posted Date
- 2009-01-01
- Last Posted Date
- 2012-12-18
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 41
- Registration Number
- NCT00816543
- Locations
- 🇰🇷
Sanofi-Aventis Administrative Office, Seoul, Korea, Republic of
Awareness to Osteopenia's Treatment by Bisphosphonate in Male Suffering From Prostate Cancer
- Conditions
- OsteoporosisProstate Cancer
- First Posted Date
- 2009-01-01
- Last Posted Date
- 2010-11-03
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 180
- Registration Number
- NCT00816452
- Locations
- 🇮🇱
Sanofi-aventis administrative office, Natanya, Israel